BIGG

Somatrogon for treating growth disturbance in children and young people aged 3 years and over

England. National Institute for Health and Care Excellence.

Année de publication: 2023

Evidence-based recommendations on somatrogon (Ngenla) for treating growth disturbance in children and young people aged 3 years and over.

Failure to Thrive/drug therapy, Growth Hormone/therapeutic use

Texte intégral

WordPress version 4.9.8
BVS-Site Plugin version 0.6.0